CCCC Q4 2024 Earnings — C4 Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

CCCCC4 Therapeutics, Inc.

$243M

Q4 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$5M+58.8% YoY

Gross Profit

$3M65.9% margin

Operating Income

-$38M-728.4% margin

Net Income

-$35M-667.8% margin

EPS (Diluted)

$-0.49

QoQ Revenue Growth

-66.3%

Cash Flow

Operating Cash Flow

-$18M

Free Cash Flow

-$18M

Stock-Based Comp.

$8M

Balance Sheet

Total Assets

$350M

Total Liabilities

$134M

Stockholders' Equity

$216M

Cash & Equivalents

$55M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$5M	$3M	+58.8%
Gross Profit	$3M	$2M	+117.3%
Operating Income	-$38M	-$37M	-0.8%
Net Income	-$35M	-$35M	+0.5%